GPCR drug designer Confo Therapeutics has announced that John Berriman was appointed as Chairman of the Board. Berriman is a known biotech veteran and has served on the boards of many biotech companies, including stem cell play ReNeuron and immunotherapeutics specialist Autolus. Most notably, Berriman was Chairman of Heptares Therapeutics, another company exclusively focused on GPCR drug development. Berriman’s insight and experience in the GPCR space will no doubt be most valuable to Confo.
Confo CEO Cedric Ververken showed great enthusiasm on the matter: “We are delighted to have attracted someone of John Berriman’s calibre to serve as Chairman of our company. John has a very impressive track record in founding, financing and growing biotech companies and his appointment is a huge asset to Confo Therapeutics as it further transitions from a technology to a drug discovery company,”
Read all Confo Therapeutics news
“I am delighted to be joining and chairing the board of Confo Therapeutics, whose technology is, I believe, one of the industry’s most promising platforms for cracking currently undruggable GPCRs, especially when an agonist is required,” Berriman commented. “I look forward to working with the board and the management team and contributing to the company’s continued evolution and growth.”